Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 304 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BioMarin Pharmaceutical Inc | BMRN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -3.50 | -3.84% | 87.70 | 07:03:48 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 91.20 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 6 | 304 | - | 76.02 - 99.56 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:24:12 | 25 | $ 87.00 | USD |
BioMarin Pharmaceutical (BMRN) Options Flow Summary
BioMarin Pharmaceutical Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 17.21B | 188.68M | - | 2.42B | 167.65M | 0.89 | 102.64 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
BioMarin Pharmaceutical News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMRN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 90.25 | 93.015 | 88.29 | 90.23 | 1,376,054 | -2.55 | -2.83% |
| 1 Month | 88.34 | 93.36 | 85.62 | 89.68 | 1,414,290 | -0.64 | -0.72% |
| 3 Months | 87.72 | 94.15 | 83.44 | 88.25 | 1,428,213 | -0.02 | -0.02% |
| 6 Months | 83.28 | 99.56 | 76.02 | 89.15 | 1,593,331 | 4.42 | 5.31% |
| 1 Year | 96.35 | 99.56 | 76.02 | 89.38 | 1,390,366 | -8.65 | -8.98% |
| 3 Years | 79.20 | 117.77 | 70.73 | 88.22 | 1,296,581 | 8.50 | 10.73% |
| 5 Years | 85.25 | 131.945 | 62.88 | 86.56 | 1,384,634 | 2.45 | 2.87% |
BioMarin Pharmaceutical Description
| BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe. |
